BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Julphar
Moodys
Fish and Richardson
Deloitte
Queensland Health
Cerilliant
Baxter
UBS
Chinese Patent Office

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,497,393

« Back to Dashboard

Summary for Patent: 8,497,393
Title:Process to prepare treprostinil, the active ingredient in Remodulin.RTM.
Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Inventor(s): Batra; Hitesh (Herndon, VA), Tuladhar; Sudersan M. (Silver Spring, MD), Penmasta; Raju (Herndon, VA), Walsh; David A. (Palmyra, VA)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:13/548,446
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 8,497,393

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap TYVASO treprostinil SOLUTION;INHALATION 022387-001 Jul 30, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-001 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-002 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-003 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-004 Dec 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-005 Oct 7, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,497,393

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,604,901 Process to prepare treprostinil, the active ingredient in Remodulin.RTM. ➤ Subscribe
8,242,305 Process to prepare treprostinil, the active ingredient in remodulin ➤ Subscribe
8,748,657 Process to prepare treprostinil ➤ Subscribe
9,593,066 Process to prepare treprostinil, the active ingredient in remodulin.RTM. ➤ Subscribe
9,156,786 Process to prepare treprostinil, the active ingredient in remodulin.RTM. ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,497,393

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2014114317 ➤ Subscribe
European Patent Office 2252570 ➤ Subscribe
South Korea 20100105852 ➤ Subscribe
Spain 2630407 ➤ Subscribe
Japan 2011506599 ➤ Subscribe
Japan 5851691 ➤ Subscribe
South Korea 101614465 ➤ Subscribe
South Korea 20160048222 ➤ Subscribe
South Korea 20170081292 ➤ Subscribe
China 103274926 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
US Department of Justice
Moodys
McKesson
AstraZeneca
Teva
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot